scholarly journals Medicare Part D Implementation and Associated Health Impact Among Older Adults in the United States

2016 ◽  
Vol 48 (1) ◽  
pp. 42-56 ◽  
Author(s):  
Cheng-Chia Chen ◽  
Hsien-Chang Lin ◽  
Dong-Chul Seo

This study examined the effect of Medicare (Part D) implementation on health outcomes among U.S. older adults. Study participants were initially extracted from the 2004–2008 Health and Retirement Study (HRS). Data from respondents who further participated in the HRS 2005–2007 Prescription Drug Study were analyzed (N = 746). This was a retrospective pre-post design with a treatment and a control group. The difference-in-differences approach with panel ordered logistic regressions was used to examine the Part D effect on three patient health outcomes before and after the implementation, controlling for patient sociodemographic characteristics. People with continuous Part D enrollment from 2006–2008 were less likely to have a worse self-rated health than those who were not enrolled in Part D (odds ratio [OR] = 0.48; p < .05). A higher Charlson Comorbidity Index score was associated with a higher likelihood of having worse self-rated overall health, worse mental health, and worse activities of daily living impairment (ORs = 1.12, 1.17, and 1.36, respectively; all ps < .001). The Part D implementation appears to have a positive effect on older adults’ overall health outcomes. A decrease in out-of-pocket cost for health care may encourage older adults to utilize more needed medications, which in turn helped maintain better health.

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. 608-608
Author(s):  
Jennifer Kirk ◽  
Sean Fleming ◽  
Denise Orwig

Abstract As the United States’ population increasingly consists of older adults aged 65+, an increase is expected in the prevalence of osteoporosis and the number of osteoporotic fractures. Bone-active medications (BAM) delay osteoporosis progression and prevent fragility fractures, but historically low treatment persistence rates and drug utilization for BAM exist among at-risk older adults. This research assessed for differences in the BAM utilization rates over five-years in Medicare Part D by provider type: geriatric specialists (GERO), generalists, specialists, nurse practitioners (NP), and physicians’ assistants (PA). This longitudinal retrospective analysis included providers with at least one BAM prescription among beneficiaries aged 65+. An analysis of response profiles was used to model the mean BAM utilization rates overall and by provider group. Of the 50,249 providers included in this analysis, 88.15% were generalists, 5.76% specialists, 1.48% GERO, 2.73% NP, and 1.87% PA. From 2013-2017, the prevalence of BAM utilization was 6%. Over the five years, BAM utilization rates did not change significantly, but provider-specific rates were significantly different (F=12.53, p&lt;.001). Provider-specific utilization rates were inconsistent with the highest utilization rates and most considerable variation observed among specialists (14.95%). PAs and NPs’ BAM utilization rates were stable at around 9.02% and 9.20%, but GERO and generalists exhibited the lowest utilization rates, 4.86% and 5.79%, respectively. While specialists had the higher-than-expected utilization rates, the overall and provider-specific BAM utilization rates were low and did not increase over time. Further research is needed to identify how provider-related factors, like geographic region and clinical training, influence underutilization.


2007 ◽  
Author(s):  
Betty E. Tanius ◽  
Stacey Wood ◽  
Yaniv Hanoch ◽  
Thomas Rice ◽  
Martina Ly ◽  
...  

2020 ◽  
Vol 383 (24) ◽  
pp. 2299-2301
Author(s):  
Stacie B. Dusetzina ◽  
Benyam Muluneh ◽  
Nancy L. Keating ◽  
Haiden A. Huskamp

2009 ◽  
Vol 49 (6) ◽  
pp. 828-838 ◽  
Author(s):  
K. A. Skarupski ◽  
C. F. Mendes de Leon ◽  
L. L. Barnes ◽  
D. A. Evans

2017 ◽  
Vol 13 (8) ◽  
pp. e694-e702 ◽  
Author(s):  
Megan E.V. Caram ◽  
Tudor Borza ◽  
Hye-Sung Min ◽  
Jennifer J. Griggs ◽  
David C. Miller ◽  
...  

Introduction: Abiraterone and enzalutamide were approved by the Food and Drug Administration in 2011 and 2012 to treat men with metastatic castration-resistant prostate cancer (mCRPC). Most men with mCRPC are > 65 years of age and thus eligible for Medicare Part D. We conducted a study to better understand the early dissemination of these drugs across the United States using national Medicare Part D data. Methods: We evaluated the number of prescriptions for abiraterone and enzalutamide by provider specialty and hospital referral region (HRR) using Medicare Part D and Dartmouth Atlas data. We categorized HRRs by abiraterone and enzalutamide prescriptions, adjusted for prostate cancer incidence, and examined factors associated with regional variation using multilevel regression models. Results: Among providers who wrote the majority of prescriptions for abiraterone or enzalutamide in 2013 (n = 2,121), 87.5% were medical oncologists, 3.3% were urologists, and 9.2% were other provider specialties. Among prescribers, approximately 30% were responsible for three quarters of the claims for abiraterone and 20% were responsible for more than half the claims for enzalutamide. Some HRRs demonstrated low-prescribing rates despite average medical oncology and urology physician workforce density. Our multilevel model demonstrated that regional factors potentially influenced variation in care. Conclusion: The majority of prescriptions written for abiraterone and enzalutamide through Medicare Part D in 2013 were written by a minority of providers, with marked regional variation across the United States. Better understanding of the early national dissemination of these effective but expensive drugs can help inform strategies to optimize introduction of new, evidence-based mCRPC treatments.


2011 ◽  
Vol 19 (12) ◽  
pp. 989-997 ◽  
Author(s):  
Julie M. Donohue ◽  
Yuting Zhang ◽  
Subashan Perera ◽  
Judith R. Lave ◽  
Joseph T. Hanlon ◽  
...  

Medical Care ◽  
2010 ◽  
Vol 48 (5) ◽  
pp. 409-417 ◽  
Author(s):  
Yuting Zhang ◽  
Judith R. Lave ◽  
Julie M. Donohue ◽  
Michael A. Fischer ◽  
Michael E. Chernew ◽  
...  

Diabetes Care ◽  
2016 ◽  
Vol 40 (4) ◽  
pp. 502-508 ◽  
Author(s):  
Yoon Jeong Choi ◽  
Haomiao Jia ◽  
Tal Gross ◽  
Katie Weinger ◽  
Patricia W. Stone ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document